43 0 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

2006 News Archive

July 31, 2006 | The Washington Post
3 Big Deals Push Venture Funding To 4-Year Peak

May 17, 2006 | Washington Business Journal
MacroGenics Raises $45M In Third Round Of Funding

News Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All